Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GM.CD40L Vaccine and CCL21 in Stage IV Lung Adenocarcinoma
NCT01433172Phase 2Completed
- Sponsor
- Moffitt Cancer Center
- Start
- Mar 2012
- Primary completion
- Jan 2016
- Modality
- Cytokines & Interferons
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of ccl21 in lung adenocarcinoma (3 arms), sponsored by Moffitt Cancer Center. Primary endpoints: Recommend Phase II Dose at 6 months and Progression Free Survival at 6 months. Started Mar 2012; status: completed.
02
Drugs
ccl21
03
Conditions
lung adenocarcinoma
Beyond the preview
Go deeper on NCT01433172.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01433172.